Quantum Surgical has acquired Johnson & Johnson’s NeuWave platform, a microwave‑ablation technology that is a core component of J&J’s robotics portfolio for cancer treatment. The deal expands Quantum’s Epione robotic platform, which is CE‑marked for abdominal, chest and musculoskeletal indications and FDA‑cleared for abdominal ablation, and strengthens its presence in the United States.
The acquisition is a strategic fit for Quantum, which is focused on expanding its Epione platform for tumor ablation. By integrating NeuWave’s microwave‑ablation technology, Quantum can offer a more comprehensive, robot‑assisted solution for percutaneous tumor ablation, a market where NeuWave’s technology is already used in more than 70 % of the top U.S. cancer centers. The deal also gives Quantum a larger footprint in the U.S. market, where it has been building a growing customer base.
For Johnson & Johnson, divesting NeuWave is part of a broader portfolio transformation that concentrates capital on high‑growth therapeutic areas. The company is sharpening its focus on oncology, immunology and MedTech initiatives, and the sale of a lower‑growth asset like NeuWave frees resources that can be redeployed into these core segments. The transaction is consistent with J&J’s recent strategy of shedding legacy assets to drive innovation and higher‑margin opportunities.
NeuWave was founded in 2004 and was acquired by J&J’s Ethicon division in March 2016. Quantum and NeuWave will operate as subsidiaries of the newly created Precision IO Group, whose CEO is Kurt Azarbarzin. The Epione platform has treated more than 1,400 patients in Europe and the U.S., and the combined entity will pursue precision and remote interventional radiology solutions that leverage AI, robotics and microwave‑ablation technology.
"As part of Quantum Surgical, NeuWave will be well positioned to continue delivering innovative products, solutions, and support to its customers. We are working closely with Quantum Surgical to help ensure a seamless transition for customers, patients, healthcare providers, employees, and other stakeholders globally," said a J&J spokesperson. "At Quantum Surgical, we are committed to democratizing procedural know-how through robotics, and expanding high‑quality cancer care for patients. Acquiring NeuWave Medical, Inc. is a natural and strategic step in that mission. Innovation is our north star and we are thrilled to join forces with a passionate team of experts to drive innovation even further and shape the future of interventional oncology," said Bertin Nahum, President and co‑founder of Quantum Surgical. "Quantum Surgical and NeuWave Medical, Inc. are highly complementary and share an incredible vision for the future. I have met both teams and am impressed by the pride and passion they bring to their work to improve patient care. Drawing on my 40 years of experience in minimally invasive surgery, I am convinced that AI, robotics and enabling remote interventions are game‑changers for cancer care and interventional radiology," added Kurt Azarbarzin.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.